ICER issues final report and policy recommendations on acute treatments for migraine

25 February 2020 - Evidence on new agents lasmiditan, ubrogepant, and rimegepant judged inadequate to demonstrate superiority over more affordable triptans. ...

Read more →

Drug pricing review group signs deal with Aetion for patient data

24 February 2020 - The Institute for Clinical and Economic Review (ICER), a small but influential Boston-based research group, has ...

Read more →

ICER and Aetion partner to develop real-world evidence for value assessment of treatments

24 February 2020 - ICER adopts Aetion’s Real-World Evidence Platform — advancing standards for the use of transparent, replicable real-world ...

Read more →

ICER to assess evidence on supervised injection facilities and digital apps for opioid use disorder

21 February 2020 - ICER expands its reviews in area of ongoing public health crisis related to opioid addiction. ...

Read more →

ICER to assess treatments for bladder cancer

20 February 2020 - Report will be subject of a Midwest CEPAC meeting in September 2020; open Input now being ...

Read more →

ICER releases draft evidence report on therapies for cystic fibrosis

20 February 2020 - Public comment period now open until 18 March 2020; requests to make oral comment during public meeting ...

Read more →

ICER methods could be illegal in US, claims US think tank

11 February 2020 - The method used by the US Institute for Clinical and Economic Review (ICER) to gauge whether ...

Read more →

ICER finalises 2020 updates to methods and public meeting procedures for value assessment framework

31 January 2020 - Reflecting experience with previous framework, benchmarking with other HTA groups, and input from more than 100 organisations ...

Read more →

ICER posts draft scoping document for the assessment of treatments for haemophilia A

24 January 2020 - Document open to public comment until 13 February 2020. ...

Read more →

ICER releases draft evidence report on therapies for sickle cell disease

23 January 2020 - ICER’s ongoing assessment emphasises that policy makers will need to consider, in addition to traditional measures ...

Read more →

ICER releases evidence report on acute treatments for migraine

10 January 2020 - Lasmiditan, rimegepant, and ubrogepant all perform better than placebo, but evidence is not adequate to distinguish among ...

Read more →

ICER issues final report and policy recommendations on JAK inhibitors for rheumatoid arthritis

9 January 2020 - Despite upadacitinib reaching common thresholds for cost-effectiveness when compared to adalimumab, the independent appraisal committee’s votes on ...

Read more →

ICER posts draft scoping document for the assessment of treatments for beta thalassaemia

6 January 2020 - Document open to public comment until 27 January 2020. ...

Read more →

ICER to assess gene therapy for haemophilia A

3 January 2020 - Report will be subject of New England CEPAC meeting in August 2020; open Input now being accepted ...

Read more →

Expanding use of multi-criteria decision analysis for health technology assessment

11 December 2019 - As America’s health care system continues to evolve, it is critical that our perception of care ...

Read more →